Executive Summary: Protect Animal Health, a Taiwan-headquartered animal health biotechnology company, has entered a long-term, multi-project collaboration with Bora Biologics, the U.S.-anchored biologics CDMO owned by Tanvex BioPharma, to develop and manufacture antibody-based veterinary products. The first wave advances at least three programs — two monoclonal antibodies and one bispecific antibody — aimed at U.S. and global animal health markets, in a segment projected to grow from US$1.7 billion in 2025 to US$3.06 billion by 2030. The commercial shelf for pets still runs on vaccines and parasiticides, from flea and tick for dogs to flea treatment for cats, while approved antibody drugs remain few.
Key Facts
- Parties
- Protect Animal Health (Taiwan, TPEX: 7850) and Bora Biologics, a DBA of Tanvex BioPharma USA (TWSE: 6541)
- Scope
- Long-term, multi-project development and manufacturing collaboration, from cell line development through scale-up and manufacturing
- First wave
- At least three antibody programs: two monoclonal antibody programs and one bispecific antibody program
- Significance
- First animal health collaboration for Bora Biologics, extending its CHO-K1 platform from human biologics into veterinary medicine
- Market size
- Global veterinary monoclonal antibody market projected from US$1.7 billion in 2025 to US$3.06 billion in 2030, CAGR 12.4 percent (MarketsandMarkets, cited by Commercial Times)
- Announced
- 4 October 2026 (ACCESS Newswire); covered by Taiwanese financial media on 5 October 2026
What Happened
Protect Animal Health and Bora Biologics announced a strategic, long-term collaboration on 4 October 2026 under which the CDMO will support development and manufacturing for Protect’s animal health pipeline. The companies expect to advance at least three antibody-based programs together, including two monoclonal antibody programs and one bispecific antibody program. The agreement spans cell line development, process development, analytical development, scale-up and manufacturing across Bora’s United States and Taiwan sites.
The deal matters commercially because of what it signals about the market it enters: approved monoclonal antibody drugs for dogs and cats remain rare, and Protect’s pipeline targets that gap with antibody and gene-therapy programs for aging-related conditions including cancer, cardiac disease and autoimmune disorders.
Background: The Companies and the Pipeline
Protect Animal Health trades on the Taipei Exchange as 7850 and runs a multi-IP, multi-pipeline strategy built around pet aging and unmet clinical needs. Its lead programs include PT001, which received clinical trial approval in Hungary, a stepping stone into the EU regulatory system, and PT401, a gene therapy for canine myxomatous mitral valve disease licensed from Harvard spinout Rejuvenate Bio for the Asia-Pacific region. Rejuvenate Bio itself drew investment from Merck Animal Health and began a strategic R&D collaboration with the animal health major in June 2026.
Bora Biologics operates as the biologics CDMO arm of Tanvex BioPharma, with development and manufacturing capacity in the United States and Taiwan. The company’s CHO-K1 cell line platform is designed for complex recombinant proteins, including monoclonal and multispecific antibody formats. For Bora, this is the first veterinary collaboration, and management framed it as a platform extension rather than a one-off contract. “This collaboration represents an important expansion of Bora Biologics’ platform into animal health,” said Jennifer Kuan, chief executive officer of Bora Biologics.
Protect president Haolin Sung said Bora brings “the technical depth, manufacturing infrastructure, and partnership mindset we need as we advance multiple programs toward the U.S. and global animal health markets.” R&D chief Feng Ching-chu told Taiwanese media that the partnership links Protect’s research output to regulatory-grade development data and commercial-scale manufacturing, strengthening the company’s position in licensing discussions with international animal health companies.
Industry Context: A Small Approved Market With Large Headroom
Monoclonal antibodies are established in companion-animal medicine in narrow pockets: Zoetis’ Librela and Solensia, anti-NGF antibodies for arthritis pain in dogs and cats, demonstrated that the format works commercially in veterinary clinics. The broader opportunity sits in chronic and life-limiting conditions where today’s toolkit is thin, which is why MarketsandMarkets projects the veterinary monoclonal antibody segment to grow from US$1.7 billion in 2025 to US$3.06 billion by 2030, a 12.4 percent compound annual rate.
Contract capacity is the bottleneck behind that forecast. Human-grade biologics facilities can serve animal health, but few CDMOs have structured offerings for veterinary regulatory pathways, and building dedicated capacity is hard to justify until pipelines mature. Partnerships of this kind move candidate molecules from academic-scale production toward the consistency and documentation that U.S. and EU filings require.
Market & Business Impact
For Protect, the collaboration converts a research-stage pipeline into a manufacturing plan with a defined regulatory route, which is the asset international partners price when licensing deals are negotiated. For Bora and Tanvex, the veterinary entry opens a second customer base for existing capacity at a time when human biologics CDMO demand is competitive. For the wider industry, the deal adds manufacturing infrastructure to the list of ingredients a veterinary biologics company needs, alongside targets, capital and clinical access.
Companies & Brands Involved
Protect Animal Health (TPEX: 7850) is headquartered in Taiwan with a development network spanning the United States, Europe and Asia. Bora Biologics, a DBA of Tanvex BioPharma USA (TWSE: 6541), provides integrated cell line, process, analytical and manufacturing services across U.S. and Taiwan facilities. Rejuvenate Bio and Merck Animal Health sit in the adjacent network through the PT401 license and June 2026 investment. Biotech and pharma players active in animal health can be profiled through the GPI company directory, and pipeline-heavy names can be compared via the GPI compare tool.
Data & Evidence
Collaboration announced 4 October 2026 via ACCESS Newswire (Bora Biologics press release, primary). Program scope: at least three antibody programs, two monoclonal and one bispecific (Bora press release; Commercial Times, 5 October 2026). Veterinary monoclonal antibody market: US$1.7 billion in 2025 to US$3.06 billion in 2030, CAGR 12.4 percent (MarketsandMarkets, cited by Commercial Times). PT001 Hungary clinical approval and PT401 Asia-Pacific license from Rejuvenate Bio (Commercial Times; CNA Money, 5 October 2026). Bora Biologics is a DBA of Tanvex BioPharma USA, TWSE: 6541 (press release).
What This Means for the Pet Industry
GPI’s read: the parasiticide-to-biologics transition just gained contract manufacturing plumbing, which is the unglamorous piece that decides whether pipelines actually reach clinics. Watch two proof points over the next year: whether any of the three programs reaches investigational new animal drug filing, and whether other Asia-Pacific biotechs copy the structure to buy their way into U.S. regulatory readiness. If they do, veterinary CDMO capacity becomes the segment’s next scarcity.
Key Takeaways
- Protect Animal Health and Bora Biologics signed a long-term, multi-project collaboration announced on 4 October 2026.
- The first wave covers at least three antibody programs: two monoclonal antibodies and one bispecific antibody.
- It is Bora’s first animal health collaboration, extending the CHO-K1 platform of Tanvex BioPharma USA into veterinary medicine.
- MarketsandMarkets projects the veterinary monoclonal antibody market to grow from US$1.7 billion in 2025 to US$3.06 billion by 2030, CAGR 12.4 percent.
- Protect’s network includes PT001’s Hungary clinical approval and the PT401 canine MMVD gene therapy licensed from Rejuvenate Bio, which counts Merck Animal Health as an investor.
Frequently Asked Questions
Why use monoclonal antibodies in pets?
Monoclonal antibodies target specific disease pathways and are already proven in veterinary clinics through arthritis pain treatments such as Librela and Solensia. The format is now extending toward cancer, cardiac and immune-mediated conditions where current options are limited.
What is heartworm disease?
Heartworm disease is a mosquito-borne parasitic infection of dogs and cats that can cause severe lung and heart damage. Prevention today relies on parasiticide products, which illustrates the market the antibody platform is moving beyond: from routine prevention toward higher-value chronic disease treatment.
Who is Bora Biologics?
Bora Biologics is the biologics contract development and manufacturing organization arm of Tanvex BioPharma USA (TWSE: 6541), with facilities in the United States and Taiwan and a CHO-K1 cell line platform for antibodies and multispecific proteins.
How big is the veterinary antibody market?
MarketsandMarkets estimates the global veterinary monoclonal antibody market at US$1.7 billion in 2025, growing to US$3.06 billion by 2030 at a 12.4 percent compound annual growth rate.
Sources
- Primary — Bora Biologics press release via ACCESS Newswire, Bora Biologics and Protect Animal Health enter strategic long-term multi-project collaboration, https://www.borabiologics.com/press-releases/bora-biologics-and-protect-animal-health-enter-strategic-long-term-multi-project-collaboration-to-advance-antibody-based-animal-health-products, 4 Oct 2026
- Secondary — Commercial Times, Bao Tai partners Tai Fu on pet drugs, three antibody programs launched, https://www.ctee.com.tw/news/20261005700569-430504, 5 Oct 2026
- Secondary — CNA via PChome, Protect Animal Health and Bora Biologics advance antibody drug programs, https://news.pchome.com.tw/finance/cna/20261005/index-17911788760548418003.html, 5 Oct 2026
